TABLE 1

Patient Characteristics and Timing of PET Scans

Patient no.	Sex	Age (y)	Stage	Location of metastasis	Time to postdosing ¹⁸F-FLT PET (d)	Time to postdosing ¹⁸F-FDG PET (d)	Toxicities during first cycle	Tumor response
GA 21	M	71	M1c	Skin, subcutaneous tissue, lymph node, liver, spleen	50	51	—	Progressive disease
GA 23	M	27	M1b	Lung	ND	36	—	Progressive disease
GA 24	M	81	M1c	Subcutaneous tissue, lung	51	52	—	Progressive disease
GA 25	M	71	M1c	Lymph node	65	ND	—	Progressive disease
GA 26	M	68	M1b	Lymph node, lung	61	72	G3 diarrhea	Progressive disease
GA 27	M	52	M1c	Lymph node	43	57	G2 pruritus	Progressive disease
GA 29	F	79	IIIc	Skin, subcutaneous tissue	61	57	G2 diarrhea	Complete response
GA 30	M	32	M1c	Skin, subcutaneous tissue, lymph node	64	65	—	Progressive disease
GA 32	M	36	M1c	Muscle	66	77	—	Progressive disease
GA 33	F	49	IIIc	Skin	98	99	—	Complete response